GETI.B

202.4

+1.43%↑

ATT

101.2

+1.4%↑

AMBEA

126.3

+2.6%↑

ARJOB

27.38

+1.33%↑

MSON.B

11.5

-1.71%↓

GETI.B

202.4

+1.43%↑

ATT

101.2

+1.4%↑

AMBEA

126.3

+2.6%↑

ARJOB

27.38

+1.33%↑

MSON.B

11.5

-1.71%↓

GETI.B

202.4

+1.43%↑

ATT

101.2

+1.4%↑

AMBEA

126.3

+2.6%↑

ARJOB

27.38

+1.33%↑

MSON.B

11.5

-1.71%↓

GETI.B

202.4

+1.43%↑

ATT

101.2

+1.4%↑

AMBEA

126.3

+2.6%↑

ARJOB

27.38

+1.33%↑

MSON.B

11.5

-1.71%↓

GETI.B

202.4

+1.43%↑

ATT

101.2

+1.4%↑

AMBEA

126.3

+2.6%↑

ARJOB

27.38

+1.33%↑

MSON.B

11.5

-1.71%↓

Search

Vivesto AB

Cerrado

0

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Métricas clave

By Trading Economics

Ingresos

2.3M

-7.2M

BPA

-0.013

Empleados

4

EBITDA

-7.1M

Dividendos

By Dow Jones

Próximas Ganancias

27 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-27M

51M

Apertura anterior

0

Cierre anterior

0

Vivesto AB Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 feb 2026, 23:25 UTC

Acciones populares

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

25 feb 2026, 23:15 UTC

Ganancias

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

25 feb 2026, 23:54 UTC

Charlas de Mercado

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

25 feb 2026, 23:47 UTC

Ganancias

Ferrovial 4Q Net EUR197M >FER.MC

25 feb 2026, 23:45 UTC

Ganancias

Ferrovial 4Q Rev EUR2.72B >FER.MC

25 feb 2026, 23:42 UTC

Ganancias

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

25 feb 2026, 23:38 UTC

Charlas de Mercado

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Company's Business Operations Remain Normal >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

25 feb 2026, 23:25 UTC

Ganancias

Trip.com FY EPS CNY47.67 >TCOM

25 feb 2026, 23:06 UTC

Ganancias

Correction to Nvidia Fourth Quarter Results Article -- WSJ

25 feb 2026, 23:01 UTC

Ganancias

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

25 feb 2026, 23:00 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

25 feb 2026, 23:00 UTC

Charlas de Mercado
Ganancias

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

25 feb 2026, 22:56 UTC

Charlas de Mercado
Ganancias

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

25 feb 2026, 22:43 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

25 feb 2026, 22:40 UTC

Charlas de Mercado
Ganancias

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

25 feb 2026, 22:40 UTC

Ganancias

Karoon Energy Says Search for New CFO Well Advanced

25 feb 2026, 22:39 UTC

Ganancias

Karoon Energy Says CFO Ray Church to Leave Company

25 feb 2026, 22:39 UTC

Ganancias

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

25 feb 2026, 22:38 UTC

Ganancias

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Comparación entre iguales

Cambio de precio

Vivesto AB previsión

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
help-icon Live chat